First-Line Treatment with Chemotherapy, Surufatinib (an Angio-Immuno Kinase Inhibitor), and Camrelizumab (an Anti-PD-1 Antibody) for Locally Advanced, or Metastatic Pancreatic Ductal Adenocarcinoma: A Phase Ib/II Randomized Study

By
Jamie Kang
-
0
60
This Phase Ib/II randomized trial investigated the efficacy and safety of surufatinib plus camrelizumab and nab-paclitaxel/S-1 versus nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic PDAC.
[Signal Transduction and Targeted Therapy]
Full Article